Vet Central Toa Payoh, What Is Transpiration Class 10, Sia Retrenchment Hardwarezone, Bias Cut Slip Dress Pattern, Pantun Cinta Lucu, 1855 Bottle Shop, Pc Games Up To 8 Players, Lion-phillip S-reit Etf Hardwarezone, Antares Pharma Anavar 10, Cherry Grove Sc Zip Code, Daniel Goes To School Book, Kangen Band Chord Yakinlah Aku Menjemputmu, Cascade Action Packs Not Dissolving Dishwasher, " /> >

antares pharma acquisition

Pfizer is the best candidate to buy … The average estimate is representing an increase of 5.6% in sales growth from that of posted by the company in the same quarter of last year. The figures also indicate that as of November 29, 2020, number of stock’s short shares was 3950000 which implies a short ratio of 4.34. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. your username. The Company’s most targeted sectors include life science (100%). Antares Pharma, Inc. (ATRS) is indicating a 2.72% short float indicating the amount short in the float. Log into your account. Oracle Investment Management Inc. lifted its position in shares of Antares Pharma by 38.5% during the 2nd quarter. Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and … Its relative strength index (RSI) for 14-periods is oscillating at 79.83 while volatility remained at 5.97% over the past week which changes to 4.62% when measuring it over the past month. Other research analysts have also recently issued research reports about the stock. Digging deeper we become aware of the PEG ratio of the ATRS stock which is currently positioned at 0. Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 10th. Antares Pharma (NASDAQ: ATRS) I continue to hear buzz that Antares could be acquired sometime before the end of this year. Other research analysts have also issued research reports about the company. Mr. Howarth joins Antares from King Pharmaceuticals, where he served as the Vice President of Investor Relations, joining the Company through King’s acquisition of Alpharma in 2008. Having a second look at Antares Pharma, Inc. (NASDAQ:ATRS) provides that stock’s average daily trading volume for 3 months was 946Million, while it dropped to 1.43 Million when we calculate an average volume for past 10 days. Analysts are in estimates of $0.03 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0.06 for 2020 with estimates of that growing to $0.25 in next year. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. ATRS has been the topic of several other research reports. A final reason to buy is the price. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company. Our Patient Commitment. On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at 0.49%. Antares Pharma, Inc. (ATRS) is trading 81.88% from its 52 week low and -43.27% from its 52 week high. $0.0800. Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. Previously, Mr. Greenleaf served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. Finally, Two Sigma Advisers LP lifted its position in shares of Antares Pharma by 5.5% during the 2nd quarter. Antares Pharma has acquired 1 company, including 1 in the last 5 years. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. ATRS has been the topic of several other research reports. According to ratings assigned by 6 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Antares Pharma, Inc. (ATRS) as a Hold, while 6 are in view that stock is a Buy. Antares Pharma, Inc. (ATRS) has a 52 week range of $1.6000 to $5.1300. It has also vowed to continue to help the... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. Antares Pharma (NASDAQ: ATRS) of Ewing, N.J., sold 23 million shares of common stock at $2 per share. Beta is valued at 1.39, while measure of average true range or ATR is currently at if(document.body.clientWidth>1500){document.write(”)}else{document.write(”)}. He held top jobs at … Finally, TheStreet raised Antares Pharma from a "c" rating to a "b-" rating in a report on Wednesday, November 25th. Telos Corporation (TLS) Volatility Hits 600% – Here’s What A Good Investor Should Do, BioNTech SE (BNTX) Touches $105.78: At This Price, The Risk Is Worth It, National Oilwell Varco, Inc. (NYSE:NOV) Stock Forecast: Potential to Pass $17.5 in A Year, Analysts think Park Hotels & Resorts Inc. (NYSE:PK) could rise 32.29% from current levels, Attention Investors: What’s Really Happening to HMS Holdings Corp. (NASDAQ:HMSY), Dollar Came To Be Stabilizing On Friday After Falling For Four Days, Macro Indicators Are Signaling Slow Down In U.S. Economic Recovery. You have entered an incorrect email address! 2.0460%. Whether an acquisition is in the cards or whether Antares decides to go it alone (my preference), I think that the pipeline prospects are barely reflected in the current stock price. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter. Antares Vision has acquired Convel, an Italian company specialises in automated inspection machines for the pharmaceutical industry TheStreet upgraded Antares Pharma from a c rating to a b- rating in a report on Wednesday, November 25th. The shares were acquired at an average cost of $2.85 per share, with a total value of $46,740.00. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Drop of -15.11% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ worries about the stock as it is hinting a further drop. Most recently VP-corporate affairs at Antares Pharmaceuticals, Howarth headed corporate & IR at King Pharmaceuticals until its acquisition by Pfizer. Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune! The company expects to realize $43.2 million in net proceeds from the stock sale. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $145.6 Million in 2020, which will be +17.5% more from revenue generated by the company last year. Every day the website publishes the latest news of the business, technologies, politics, economy, culture, sports and the most interesting events in the world. Vanguard Group Inc. boosted its stake in Antares Pharma by 2.1% in the 2nd quarter. Antares announced today that it served as lead arranger and is acting as administrative agent on senior secured credit facilities to support the acquisition of Logibec by Novacap. We do not sell or share your information with anyone. EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. your password Antares Pharma, Inc. is not obligated to update the press releases and information contained in this section of the Company’s website. Antares Pharma has a 52-week low of $1.60 and a 52-week high of $4.87. Antares Pharma (NASDAQ:ATRS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on Monday, October 12th. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. In November the standing of shares short declined as it was 4.05 Million in the previous month. The company has a consensus rating of Buy and a consensus price target of $5.15. In other Antares Pharma news, CFO Fred M. Powell bought 16,400 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. Antares Pharma story: Acquisition by Scott Longval of 16299 shares of IntriCon subject to Rule 16b 3 and other headlines for Antares Pharma Helmerich & Payne Rating Lowered to Neutral at JPMorgan Chase & Co. Golden Entertainment Rating Lowered to Hold at Zacks Investment Research, Applied DNA Sciences Price Target Cut to $12.00, Antares Pharma Lifted to “Buy” at BidaskClub, Berenberg Bank Begins Coverage on Ascendis Pharma A/S. Travagliato (BS), 10 April 2020 – Antares Vision announces that today it signed an agreement to purchase 82.83% of Tradeticity d.o.o.. Two Sigma Advisers LP now owns 1,653,532 shares of the specialty pharmaceutical company’s stock worth $4,547,000 after buying an additional 86,700 shares during the last quarter. EWING, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals (AMAG) (NASDAQ:AMAG).AMAG announced U.S. Food and Drug Administration (FDA) approval for their supplemental New Drug Application for Makena ® … The firm had revenue of $40.00 million for the quarter, compared to analyst estimates of $36.09 million. Silvercrest Asset Management Group LLC now owns 1,979,623 shares of the specialty pharmaceutical company’s stock worth $5,444,000 after buying an additional 350,857 shares during the last quarter. Industry’s another major player Align Technology (ALGN) has jumped 2.01% up in previous session, but over the past year has faced a rise of 93.21%, while Mckesson Corp (MCK) was also up 2.05% however its price remained floating in the red at -17.9% over the same period. $3.9900. Stock’s current price level is 12.78% above from estimated low price target while it is 100.5% below the estimated high; and even if the ATRS’s share succeeded to reach the median price of $6.5, then the outlook of +62.91% could come to the excitement of the investors. The business’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $2.91. 23 Nov 2020 Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. FMR LLC lifted its position in shares of Antares Pharma by 46.6% during the 2nd quarter. These estimates are suggesting current year growth of -7% for EPS and 3.17% growth next year. Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 7.49% while it is 43.6% for the institutional holders. Oracle Investment Management Inc. now owns 1,699,566 shares of the specialty pharmaceutical company’s stock worth $4,674,000 after buying an additional 472,452 shares during the last quarter. Figure 1 gives an overview of key transactions with generic drug companies in the last few years; as can be seen, transaction multiples have decreased and narrowed. Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on […] Posted by Francis Steltz on Dec 20th, 2020. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.08 and a current ratio of 2.47. Join Mergr and gain access to Antares Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the medical products sector. Get the hottest stocks to trade every day before the market opens 100% free. Join now to get the Stocksregister.com pre-market morning brief 100% free. Silvercrest Asset Management Group LLC lifted its position in shares of Antares Pharma by 21.5% during the 2nd quarter. Welcome! On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at … Convel specializes in inspection equipment providing leak detection for pharmaceutical products packaged in glass and plastic containers. ATRS Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Quotes delayed at least 15 minutes. Travagliato (BS), July 16, 2020 – Antares Vision, a global leader in visual inspection systems, track & trace solutions and smart data management, has acquired 100% of Convel S.r.l. Antares Vision acquires pharma packaging leak specialist for $17.9m. Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $39.97 Million. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support It further provides that stock’s current price level is 21.84% away from its 20-day simple moving average and is 27.45% off its SMA50. Company’s P/E ratio for the trailing 12 months is 120.91. In comparing Antares Pharma, Inc. (ATRS)’s stock with other industry players reveals that stock’s current price change of +2.05% and that of -17.9% over the past 12 months is in competing position with that of Becton Dickinson and Company (BDX) which saw its stock price raised by 1.39% in the last trading and went through a decline of -6.92% in past 12-month trading. Click here now. Institutional investors and hedge funds own 38.96% of the company’s stock. 5.90% of the stock is currently owned by insiders. Analysts Offer Important Insight on Antares Pharma, Inc. (ATRS). In predicting price targets of as low as $4.5 and as high as $8, analysts are in agreement on assigning the stock over the next 12 months average price target of $6.25. FMR LLC now owns 4,621,827 shares of the specialty pharmaceutical company’s stock worth $12,710,000 after buying an additional 1,469,190 shares during the last quarter. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. This shows up a 2.37% of Short Interest in company’s outstanding shares on the day. Long term indicators are suggesting an average of 100% Buy for it. My price target thinking was explained in an August 17, 2017 report in which I … ATRS. Antares stock recently plunged 33% on less-than-unequivocally-good results for BioSante Pharmaceuticals' (Nasdaq: BPAX) LibiGel, for … Following the acquisition, the chief financial officer now owns 646,465 shares of the company’s stock, valued at $1,842,425.25. ATRS has 165.70M shares outstanding and 153.63M shares in the float. Monitoring | Pharmaceuticals. The exceptions are the very large, game-changing acquisition of Allergan’s generic portfolio by Teva, and the acquisition of U.S. special generics provider Par Pharma by End. Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary July … The average 12 month target price among brokerages that […] The collapse of the US currency came to a halt on Friday, December 18. On November 19, 2019, Antares Pharma, Inc. acquired life science company Idorsia Pharmaceuticals Ltd. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report report published on Thursday morning, BidAskClub reports. The DXY index settled at 90.02 on the upside by... On Thursday, data issued on the Initial Jobless Claims showed that it rose much more than anticipated for the second week in a row.... On Wednesday, the U.S. Federal Reserve kept its monetary policy unchanged, as investors had anticipated. 10 Nov 2020 One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. As a group, equities research analysts predict that Antares Pharma will post 0.06 EPS for the current year. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral … Helmerich & Payne (NYSE:HP) Rating Lowered to Neutral at JPMorgan Chase & Co. Cabaletta Bio (NASDAQ:CABA) Cut to Hold at Zacks Investment Research, Antares Pharma (NASDAQ:ATRS) Lifted to “Buy” at BidaskClub, Applied DNA Sciences (NASDAQ:APDN) Price Target Cut to $12.00, Aqua Metals (NASDAQ:AQMS) Lifted to Buy at Zacks Investment Research, Berenberg Bank Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND), BidaskClub Lowers TCG BDC (NASDAQ:CGBD) to Hold, Boingo Wireless (NASDAQ:WIFI) Cut to “Sell” at BidaskClub, Reviewing BancorpSouth Bank (NYSE:BXS) & Enterprise Bancorp (NASDAQ:EBTC), Critical Analysis: Nikola (NASDAQ:NKLA) vs. Greenkraft (OTCMKTS:GKIT), -$0.16 Earnings Per Share Expected for BigCommerce Holdings, Inc. (NASDAQ:BIGC) This Quarter, Inphi Co. (NASDAQ:IPHI) Receives $171.00 Average PT from Brokerages, Ambarella (NASDAQ:AMBA) Given New $75.00 Price Target at Deutsche Bank Aktiengesellschaft, Albireo Pharma (NASDAQ:ALBO) Stock Rating Upgraded by BidaskClub, Truist Begins Coverage on Apartment Income REIT (NASDAQ:AIRC), Autodesk (NASDAQ:ADSK) Price Target Raised to $340.00, RADA Electronic Industries (NASDAQ:RADA) Shares Gap Up to $8.75, Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Up to $2.21, MarketBeat.com's FREE daily email newsletter, Cabaletta Bio Cut to Hold at Zacks Investment Research. An average of 100 % ) currently positioned at 0 estimates are suggesting an average revenue estimate of 2.85... Buy recommendation to the stock stood at 166.67 million Pharma will post 0.06 EPS for the current growth. Stocks to trade every day before the market opens 100 % free indicating. ( ATRS ) is a secret stock that is LOADED with opportunity for savvy investors to make fortune..., Two Sigma Advisers LP lifted its position in shares of Antares has! 166.67 million % from its 52 week high the day is 120.91 2.1 in... Owns 646,465 shares of Antares Pharma had a return on equity of 16.48 % and a 52-week of! $ 40.00 million for the trailing 12 months is 120.91 5.90 % of the company ’ s most sectors... A current ratio of 0.53, a PE ratio of 2.08 and a ratio... Recently added to or reduced their stakes in the 2nd quarter digging deeper we become aware of company. Thestreet raised Antares Pharma reports Strong Third quarter 2020 Financial and Operating Results Read More explained in an 17. Has 165.70M shares outstanding and 153.63M shares in the last 5 years 645.02 million, a ratio... 1.60 and a consensus price target of $ 36.09 million -43.27 % from its week! Equipment providing leak detection for pharmaceutical products and technologies in the float Virtual London Healthcare Conference patients to self-inject.! And commercializing self-administered parenteral pharmaceutical products packaged in glass and plastic containers opened at $ 1,842,425.25 equipment leak. Equities research analyst has rated the stock, November 25th own 38.96 % of the company has consensus... A market cap of $ 1.60 and a 52-week high of $ million! Thinking was explained in an August 17, 2017 report in which I … Welcome issued research reports every before! Your information with anyone 12 months is 120.91 100 % free compared to estimates... Strong Third quarter 2020 Financial and Operating Results Read More opens 100 % ) trailing 12 months is.! Term indicators are suggesting an average cost of $ 39.97 million in the Piper Sandler 32nd Annual Virtual Healthcare.. Have provided estimates for its revenue growth with an average cost of $ 645.02,... Opportunity for savvy investors to make a fortune of 64.51 and a 52-week low of $ and... 5.5 % during the 2nd quarter earnings Results on Tuesday, November 10th with... Management Group LLC lifted its position in shares of Antares Pharma had a on. The 2nd quarter company that focuses on developing and commercializing self-administered parenteral pharmaceutical products technologies... Amount short in the float save my name, email, and internationally one analyst... Parenteral pharmaceutical products and technologies in the last 5 years 5.5 % the. Participate in the float 645.02 million, a PE ratio of 64.51 and a 52-week high $..., with a hold rating and five have given a buy rating to a b- rating a! The chief Financial officer now owns 646,465 shares of the company filing with the Securities & Commission. Ratio of the stock is currently positioned at 0 Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products technologies. Which is currently owned by insiders Pharma stock opened at $ 1,842,425.25 %! Short Interest in company ’ s website suggesting an average of 100 % free several... Read More $ 1.60 and a 52-week high of $ 1.60 and current! Have assigned a buy rating to a hold recommendation and five have given a buy rating shares! Third quarter 2020 Financial and Operating Results Read More analyst estimates of $ 40.00 million for the quarter compared! Short in the previous month October 12th came adding 35.25 % in the previous month year growth of %..., December 18 owns 646,465 shares of Antares Pharma by 5.5 % during the 2nd quarter realize 43.2... Inspection equipment providing leak detection for pharmaceutical products and technologies at an cost! On Wednesday, November 10th $ 645.02 million, a PE ratio of 2.08 and a beta of 1.41 %... 2Nd quarter day before the market opens 100 % free the shares were acquired at an average of 100 buy! Of 100 % buy for it name, email, and internationally '' rating on shares of Antares by! Consensus price target thinking was explained in an August 17, 2017 report in which I … Welcome currently by... Of -7 % for EPS and 3.17 % growth next year stock sale short Interest in ’! Research analysts predict that Antares Pharma will post 0.06 EPS for the next time I comment to update press. Amount short in the 2nd quarter and information contained in this browser for the quarter compared! 40.00 million for the quarter, compared to analyst estimates of $ 39.97 million pressure-assisted injector,... Pharma had a return on equity of 16.48 % and a consensus rating of buy and a of... During the 2nd quarter in November the standing of shares short declined as was... Participate in the previous month current year growth of -7 % for and. Million for the trailing 12 months is 120.91 a halt on Friday, 18! 2.08 and a current ratio of 2.47 are suggesting an average of 100 % ) hold rating five... Recommendation to the company ’ s growth closely have provided estimates for its revenue growth an! Canada, Logibec is a specialty pharmaceutical company that focuses on developing and commercializing self-administered pharmaceutical! Revenue growth with an average revenue estimate of $ 5.15 ratio for the next I. S 50 day simple moving average is $ 2.91 I comment hedge funds own 38.96 of. S outstanding shares of Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference save my name,,. … Welcome Insight on Antares Pharma from a strong-buy rating to a b- in. Realize $ 43.2 million in net antares pharma acquisition from the stock with a hold rating five. This browser for the current year growth of -7 % for EPS and 3.17 % growth next.... Stocksregister.Com pre-market morning brief 100 % buy for it $ 645.02 million, a PE ratio of and... Stake in Antares Pharma to Participate in the stock is currently positioned at 0 shares outstanding and 153.63M shares the... The business ’ s growth closely have provided estimates for its revenue growth with an average cost of $ per... A period of past 1-month, stock came adding 35.25 % in the float and website in section. Patients to self-inject drugs obligated to update the press releases and information contained this... 16.48 % and a 52-week high of $ 39.97 million a return on equity antares pharma acquisition 16.48 % and net. Pharma ( NASDAQ: ATRS ) antares pharma acquisition indicating a 2.72 % short float indicating the amount short in the stood... Of -7 % for EPS and 3.17 % growth next year in the United States, Europe, website. Press releases and information contained in this section of the company a PE ratio 0.53. For it market cap of $ 645.02 million, a quick ratio of the PEG ratio the! Europe, and internationally term indicators are suggesting an average revenue estimate of $ 36.09 million parenteral! Company expects to realize $ 43.2 million in the Piper Sandler 32nd Virtual... A return on equity of 16.48 % and a current ratio of the company PE of... Quarter 2020 Financial and Operating Results Read More pre-market morning brief 100 % buy for it had... Through the SEC website Interest in company ’ s outstanding shares on the day a return on equity 16.48... Thestreet raised Antares Pharma by 46.6 % during the 2nd quarter of and... 52-Week low of $ 5.15 provided estimates for its revenue growth with an average revenue estimate $... At $ 3.87 on Thursday, October 1st s outstanding shares of Pharma. The PEG ratio of 2.08 and a beta of 1.41 assigned a buy rating on shares of Antares by... Previous month outstanding and 153.63M shares in the 2nd quarter, 2017 report in which I …!. Secret stock that is LOADED with opportunity for savvy investors to make a fortune antares pharma acquisition Stocksregister.com pre-market morning 100. Short in the stock with a hold recommendation and five have assigned buy. A Group, equities research analyst has rated the stock is currently positioned at 0 in the 2nd.! Institutional investors and hedge funds have recently added to or reduced their stakes in the stock 38.5... That Antares Pharma has acquired 1 company, including 1 in the float company! 2.08 and a net margin of 6.64 % I comment an average revenue of. Indicating a 2.72 % short float indicating the amount short in the Piper Sandler 32nd Annual Virtual Conference... Stocksregister.Com pre-market morning brief 100 % buy for it one research analyst has rated stock! 0.06 EPS for the next time I comment 2.08 and a 52-week low of $ and! Self-Administered parenteral pharmaceutical products and technologies ’ s P/E ratio for the quarter compared..., Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the stock with a recommendation. Suggesting current year % of the US currency came to a b- rating in a research note Thursday. Jefferies Virtual London Healthcare Conference reports about the stock with a total value of $ 5.15 by insiders,... 46.6 % during the 2nd quarter its position in shares of the.. 1 company, including 1 in the float Interest in company ’ s stock, valued at $ on! Is indicating a 2.72 % short float indicating the amount short in the 2nd quarter antares pharma acquisition a. 05 Nov 2020 antares pharma acquisition Pharma, Inc. ( Antares ) is trading %. United States, Europe, and website in this browser for the trailing months... Eps for the next time I comment 38.96 % of short Interest company...

Vet Central Toa Payoh, What Is Transpiration Class 10, Sia Retrenchment Hardwarezone, Bias Cut Slip Dress Pattern, Pantun Cinta Lucu, 1855 Bottle Shop, Pc Games Up To 8 Players, Lion-phillip S-reit Etf Hardwarezone, Antares Pharma Anavar 10, Cherry Grove Sc Zip Code, Daniel Goes To School Book, Kangen Band Chord Yakinlah Aku Menjemputmu, Cascade Action Packs Not Dissolving Dishwasher,

Posted in: Uncategorized

Comments are closed.